Desmopressin for the treatment of adult nocturia

Therapy

Volumn 5, Issue 5, 2008, Pages 667-683

  Hashim, Hashim ^a   Abrams, Paul ^a  

^a SOUTHMEAD HOSPITAL   (United Kingdom)

Author keywords

blockers; Antimuscarinics; Desmopressin; Hyponatremia; Nocturia; Nocturnal polyuria; Pharmacodynamics; Pharmacokinetics; Quality of life; Vasopressin

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BUMETANIDE; DESMOPRESSIN; DESMOPRESSIN ACETATE; DESMOTABS; ESTROGEN; FUROSEMIDE; LOOP DIURETIC AGENT; MELATONIN; MUSCARINIC RECEPTOR BLOCKING AGENT; OCTIM; PLACEBO; SOLIFENACIN; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TOLTERODINE; TROSPIUM CHLORIDE; UNCLASSIFIED DRUG; VASOPRESSIN;

ABDOMINAL PAIN; ANAMNESIS; ARTICLE; BEDTIME DOSAGE; BENIGN PROSTATE OBSTRUCTION; CLINICAL PROTOCOL; CLINICAL TRIAL; CONSERVATIVE TREATMENT; DIARRHEA; DISEASE CONTROL; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG EXCRETION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FLUID THERAPY; HEART FAILURE; HUMAN; HYPERTENSION; HYPONATREMIA; INCIDENCE; INSOMNIA; LIFESTYLE MODIFICATION; MEDICAL ASSESSMENT; MICTURITION DISORDER; NAUSEA; NOCTURIA; OVERACTIVE BLADDER; PERIPHERAL EDEMA; PHARMACODYNAMICS; POLYURIA; POSTMARKETING SURVEILLANCE; PROSTATE DISEASE; SIDE EFFECT; THORAX PAIN; URINARY FREQUENCY; URINARY TRACT INFECTION; VERTIGO; VOMITING; XEROSTOMIA;

EID: 64849100349     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.2217/14750708.5.5.667     Document Type: Article

References (81)

1. van Kerrebroeck P, Abrams P, Chaikin D el al.: The standardisation of terminology in nocturia: report from the Standardisation Sub-committee of the International Continence Society. Neurourol. Urodyn. 21 (2), 179-183 (2002).
2. Irwin DE, Milsom I, Hunskaar S et al.: Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur. Urol. 50(6), 1306-1314 (2006).
3. Jolleys JV, Donovan JL, Nanchahal K, Peters TJ, Abrams P: Urinary symptoms in the community: how bothersome are they? Br. J. Urol. 74(5), 551-555 (1994).
4. Swithinbank LV, Donovan J, Shepherd AM, Abrams P: Female urinary symptoms: just how much "bother" are they? (Abstract 59A). Neurourol. Urodyn. 16(5) 431-432 (1997).
5. Asplund R, Aberg H: Nocturnal micturition, sleep and well-being in women of ages 40-64 years. Maturitas 24(1-2), 73-81 (1996).
6. Roth T: Prevalence, associated risks, and treatment patterns of insomia. J. Clin. Psychiatry 66(Suppl. 9), 10-13 (2005).
7. Kobelt G, Borgstrom F, Mattiasson A: Productivity, vitality and utility in a group of healthy professionaly active individuals with nocturia. BJU Int. 91(3), 190-195 (2003).
8. Asplund R: Hip fractures, nocturia, and nocturnal polyuria in the elderly. Arch. Gerontol. Geriatr. 43(3), 319-326 (2006).
9. Avery K, Hashim H, Gardener N, Abrams P, Donovan J, Abraham L: Development and psychometric evaluation of the ICIQ nocturia module: the ICIQ-N. Presented at: International Continence Society Annual Conference. Paris, France, August 25-27 2004 (Abstract 595)
10. Brubaker L, Fitzgerald MP: Nocturnal polyuria and nocturia relief in patients treated with solifenacin for overactive bladder symptoms. Int. Urogynecol. J. Pelvic. Floor Dysfunct. 18(7), 737-741 (2007).
11. Chapple CR, Cardozo L, Steers WD. Govier FE: Solifenacin significantly improves all symptoms of overactive bladder syndrome. Int. J. Clin. Pract. 60(8), 959-966 (2006).
12. Nitti VW, Dmochowski R, Appell RA, Wang JT, Bavendam T, Guan Z: Efficacy and tolerability of tolterodine extended-release in continent patients with overactive bladder and nocturia. BJU Int. 97(6), 1262-1266 (2006).
13. Rackley R, Weiss JP, Rovner ES, Wang JT, Guan Z: Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia. Urology 67(4), 731-736. (2006).
14. Rudy D, Cline K, Harris R, Goldberg K, Dmochowski R: Multicenter Phase III trial studying trospium chloride in patients with overactive bladder. Urology 67(2), 275-280 (2006).
15. Norgaard JP, Hashim H, Malmberg L, Robinson D: Antidiuresis therapy: mechanism of action and clinical implications. Neurourol. Urodyn. 26(7), 1008-1013 (2007).
16. Swithinbank LV, Vestey S, Abrams P: Nocturnal polyuria in community-dwelling women. BJU Int. 93(4), 523-527 (2004).
17. Yoshimura K, Ohara H, Ichioka K et al.: Nocturia and benign prostatic hyperplasia. Urology 61(4), 786-790 (2003).
18. Djavan B, Milani S, Davies J, Bolodeoku J: The impact of tamsulosin oral controlled absorption system (OCAS) on nocturia and the quality of sleep: preliminary results of a pilot study. Eur. Urol. 4 (Suppl. 2) 61-68. (2005).
19. Rembratt A, Norgaard JP, Andersson KE: What in nocturnal polyuria? BJU Int. 90(Suppl. 3), 18-20 (2002).
20. Yoong HF, Sundaram MB, Aida Z: Prevalence of nocturnal polyuria in patients with benign prostatic hyperplasia. Med. J. Malaysia 60(3) 294-296 (2005).
21. Reynard JM, Cannon A, Yang Q, Abrams P: A novel therapy for nocturnal polyuria: a double-blind randomized trial of frusemide against placebo. Br. J. Urol. 81(2), 215-218 (1998).
22. Pedersen PA, Johansen PB: Prophylactic treatment of adult nocturia with bumetanide. Br. J. Urol. 62(2), 145-147 (1998).
23. Kok AL, Burger CW, van de Weijer PH, Voetberg GA, Peters-Muller ER, Kenemans P: Micturition complaints in postmenopausal women treated with continously combined hormone replacement therapy: a prospective study. Maturitas 31(2), 143-149 (1999).
24. Drake MJ, Mills IW, Noble JG: Melatonin pharmacotherapy for nocturia in men with benign prostatic enlargement. J. Urol. 171(3), 1199-1202 (2004).
25. Anderson KE, Appell R, Cardozo L et al.: Pharmacological treatment of urinary incontinence. In: Incontinence (3rd International Consultation on Incontinence Edition). Abrams P, Cardozo L, Khoury S, Wein A (Eds) Health Publication Ltd, Paris, France, 809-854 (2005).
26. Fonda D, DuBeau C, Harari D, Ouslander JG, Palmer M, Roe R: Incontinence in the frail elderly. In: Incontinence (3rd International Consultation on Incontinence Edition). Abrams P, Cardozo L, Khoury S, Wein A (Eds) Health Publication Ltd, Paris France, 1163-1240 (2005).
27. du Vigneaud V: Hormones of the posterior pituitary gland: oxytocin and vasopressin. Harvey Lect. 50, 1-26 (1954).
28. Archer R, Light A, du Vigneaud V: Purificaion of oxytocin and vasopressin by way of a protein. complex. J. Biol. Chem. 233(1) 116-120 (1958).
29. Turner RA, Pierce JG, du Vigneaud V: The purification and the amino acid content of vasopressin preparations. J. Biol. Chem. 191(1), 21-28 (1951).
30. Kimbrough RDJ, Cash WD, Branda LA, Chan WY, Du Vigneaud V: Synthesis and biological properties of 1-desamino-8-lysine-vasopressin. J. Biol. Chem. 238, 1411-1414 (1963).
31. Studer RO, Cash WD: Synthesis of 1-acetyl-8-argininevasopressin and a study of its effects in the rat pressor assay. J. Biol. Chem. 238, 657-659 (1963).
32. Vavra I, Machova A, Krejci I: Antidiuretic action of 1-deamino-(8-D-arginine)-vasopressin in unanesthetized rats. J. Pharmacol. Exp. Ther. 188(1), 241-247 (1974).
33. Anderson KE, Arner B: Effects of DDAVP, a synthetic analogue of vasopressin, in patients with cranial diabetes insipidus. Acta Med. Scand. 192(1-2), 21-27 (1972).
34. Andersson KE, Arner B, Hedner P, Mulder JL: Effects of 8-lysine-vasopressin and synthetic analogues of release of ACTH. Acta Endocrinol. (Copenh.) 69(4), 640-648 (1972).
35. Edwards CR, Kitau MJ, Chard T, Besser GM: Vasopressin analogue DDAVP in diabetes insipidus: clinical and laboratory studies. Br. Med. J. 3(5876), 375-378 (1973).
36. Robinson AG: DDAVP in the treatment of central diabetes insipidus. N. Engl. J. Med. 294(10), 507-511 (1976).
37. Dimson SB: Desmopressin as a treatment for enuresis. Lancet 1 (8024), 1260 (1977).
38. Tuvemo T: DDAVP in childhood nocturnal enuresis. Acta Paediatr. Scand. 67(6), 753-755 (1978).
39. Puri VN: Urinary levels of antidiuretic hormone in nocturnal enuresis. Indian Pediatr. 17(8), 675-676 (1980).
40. Norgaard JP, Pedersen EB, Djurhuus JC: Diurna anti-diuretic-hormone levels in enuretics. J. Urol. 134(5), 1029-1031 (1985).
41. Mansson W, Sundin T, Gullberg B: Evaluation of a synthetic vasopressin analogue for treatment of nocturia in benign prostatic hypertrophy. A double-blind study. Scand. J. Urol. Nephrol. 14(2), 139-141 (1980).
42. Hilton P, Hertogs K, Stanton SL: The use of desmopressin (DDAVP) for nocturia in women with multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 46(9), 854-855 (1983).
43. Valiquette G, Abrams GM, Herbert J: DDAVP in the management of nocturia in multiple sclerosis. Ann. Neurol. 31(5), 577 (1992).
44. Eckford SD, Swami KS, Jackson SR, Abrams PH: Desmopressin in the treatment of nocturia and enuresis in patients with multiple sclerosis. Br. J. Urol. 74 (6), 733-735 (1994).
45. Eckford SD, Carter PG, Jackson SR, Penney MD, Abrams P: An open, in-patient incremental safety and efficacy study of desmopressin in women with multiple sclerosis and nocturia. Br. J. Urol. 76(4), 459-463 (1995).
46. Valiquette G, Herbert J, Maede-D'Alisera P: Desmopressin in the management of nocturia in patients with multiple sclerosis A double-blind, crossover trial. Arch. Neurol. 53(12), 1270-1275 (1996).
47. Fredrikson S: Nasal spray desmopressin treatment of bladder dysfunction in patients with multiple sclerosis. Acta Neurol. Scand. 94(1), 31-34 (1996).
48. Valiquette G, Herbert J, Maede-D'Alisera P: Desmopressin in the management of nocturia in patients with multiple sclerosis. A double-blind, crossover trial. Arch. Neurol. 53(12), 1270-1275 (1996).
49. Ferreira E, Letwin SR: Desmopressin for nocturia and enuresis associated with multiple sclerosis. Ann. Pharmacother: 32 (1), 114-116 (1998).
50. Suchowersky O, Furtado S, Rohs G: Beneficial effect of intranasal desmopressin for nocturnal polyuria in Parkinson's disease. Mov. Disord. 10(3), 337-340 (1995).
51. Fjellestad-Paulsen A, Hoglund P, Lundin S, Paulsen O: Pharmacokinetics of 1-deamino-8-D-arginine vasopressin after various routes of administration in healthy volunteers. Clin. Endocrinol. (Oxf.) 38(2), 177-182 (1993).
52. Vilhardt H, Lundin S: Biological effect and plasma concentrations of DDAVP after intranasal and peroral administration to humans. Gen. Pharmacol. 17(4), 481-483 (1986).
53. d'Agay-Abensour L, Fjellestad-Paulsen A, Hoglund P, Ngo Y, Paulsen O, Rambaud JC: Absolute biovailability of an aqueous solution of 1-deamino-8-D-arginine vasopressin from different regions of the gastrointestinal tract in man. Eur J. Clin. Pharmacol. 44(5), 473-476 (1993).
54. Rembratt A, Graugaard-Jensen C, Senderovitz T, Norgaard JP, Djurhuus JC: Pharmacokinetics and pharmacodynamics of desmopressin administered orally versus intravenously at daytime versus night-time in healthy men aged 55-70 years. Eur. J. Clin Pharmacol. 60(6), 397-402 (2004).
55. Callreus T, Hoglund P: Pharmacokinetics and antidiuretic effect of intravenous administration of desmopressin in orally overhydrated male volunteers. Pharmacol. Toxicol. 83(6), 259-262 (1998).
56. Rittig S, Jensen AR, Jensen KT, Pedersen EB: Effect of food intake on the pharmacokinetics (DDAVP) in hydrated normal subjects. Clin. Endocrinol. (Oxf.) 48(2), 235-241 (1998).
57. Stegner H, Artman HG, Leake RD, Fisher DA: Does DDAVP (1-desamino-8-D-arginine-vasopressin) cross the blood-CSF barrier? Neuroendocrinology 37(4), 262-265 (1983).
58. Sorensen PS, Vilhardt H, Gjerris F, Warberg J: Impermeability of the blood-cerebrospinal fluid barrier to 1-deamino-8-D-arginine-vasopressin (DDAVP) in patients with acquired, communication hydrocephalus. Eur. J. Clin Invest. 14(6), 435-439 (1984).
59. Vilhardt H, Lundin S, Falch J: Plasma kinetics of DDAVP in man. Acta Pharmacol. Toxicol. (Copenh.) 58(5), 379-381 (1986).
60. Hvistendahl GM, Riis A, Norgaard JP, Djurhuus JC: The pharmacokinetics of 400 μg of oral desmopressin in elderly patients with nocturia, and the correlation between the absorption of desmopressin and clinical effect. BJU Int. 95(6), 804-809 (2005).
61. Salvatore S, Hill S, Cardozo L, Khullar V, Boos K, Athanasiou S: Safety assessment of high dose of oral desmopressin (Abstract 162). Int Urogynecol J. 8(1), S132 (1997).
62. Asplund R, Sundberg B, Bengtsson P: Desmopressin for the treatment of nocturnal polyuria in the elderly: a dose titration study. Br. J. Urol. 82(5), 642-646 (1998).
63. Asplund R, Sundberg B, Bengtsson P: Oral desmopressin for nocturnal polyuria in elderly subjects: a double-blind, placebo-controlled randomized exploratory study. BJU Int. 83(6), 591-595 (1999).
64. Asplund R, Aberg H: Desmopressin in elderly women with increased nocturnal diuresis. A short-term study. Br. J. Urol. 72(10, 42-45 (1993).
65. Asplund R, Aberg H; Desmopressin in elderly subjects with increased nocturnal diuresis. A two-month treatment study. Scand. J. Urol. Nephrol. 27(1), 77-82 (1993).
66. Chancellor MB, Atan A, Rivas DA, Watanabe T, Tai HL, Kumon H: Beneficial effect of intranasal desmopressin for men with benign prostatic hyperplasia and nocturia: preliminary results. Tech. Urol. 5(4), 191-194 (1999).
67. Kuo HC: Efficacy of desmopressin in treatment of refractory nocturia in patients older than 65 years. Urology 59(4), 485-489 (2002).
68. Hilton P, Stanton SL: The use of desmopressin (DDAVP) in nocturnal urinary frequency in the female. Br. J. Urol. 54(3), 252-255 (1982).
69. Mattiasson A, Abrams P, Van Kerrebroeck P, Walter S, Weiss J: Efficacy of desmopressin in the treatment of nocturia: a double-blind placebo-controlled study in men. BJU Int. 89(9), 855-862 (2002).
70. Lose G, Lalos O, Freeman RM, Van Kerrebroeck P: Efficacy of desmopressin (Minirin) in the treatment of nocturia: a double-blind placebo-controlled study in women. Am. J. Obstet. Gynecol. 189(4), 1106-1113 (2003).
71. Van KP, Rezapour M, Cortesse A, Thuroff J, Riis A, Norgaard JP: Desmopressin in the treatment of nocturia: a double-blind, placebo-controlled study. Eur. Urol. 52(1), 221-229 (2007).
72. Lose G, Mattiasson A, Walter S. et al.: Clinical experiences with desmopressin for long-term treatment of nocturia. J. Urol. 172(3), 1021-1025 (2004).
73. Rembratt A, Norgaard JP, Andersson KE: Desmopressin in elderly patients with nocturia: short-term safety and effects on urine output, sleep and voiding patterns. BJU Int. 91(7), 642-646 (2003).
74. Weatherall M: The risk of hyponatremia in older adults using desmopressin for nocturia: a systematic review and meta-analysis. Neurourol. Urodyn. 23(4), 302-305 (2004).
75. Rembratt A, Riis A, Norgaard JP: Desmopressin treatment in nocturia; an analysis of risk factors for hyponatremia. Neurourol. Urodyn. 25(2), 105-109 (2006).
76. Callreus T, Ekman E. Andersen M: Hyponatremia in elderly patients treated with desmopressin for nocturia: a review of a case series. Eur. J. Clin Pharmacol. 61(4), 281-284 (2005).
77. Bae JH, Oh MM, Shim KS et al.: The effects of long-term administration of oral desmopressin on the baseline secretion of antidiuretic hormone and serum sodium concentration for the treatment of nocturia: a circadain study. J. Urol. 178(1), 200-203 (2007).
78. Vande Walle J, Stockner M, Raes A, Norgaard JP: Desmopressin 30 years in clinical use: a safety review. Curr. Drug Safety 2(3), 232-238 (2007).
79. De Guchtenaere A, Vande Walle C, Van Sintjan P et al.: Nocturnal polyuria is related to absent circadian rhythm of glomerular filtration rate. J. Urol. 178(6), 2626-2629 (2007).
80. Carter PG, Cannon A, McConnell AA, Abrams P: Role of atrial natriuretic peptide in nocturnal polyuria in elderly males. Eur. Urol. 36(3), 213-220 (1999).
81. Vilhardt H: Basic pharmacology of desmopressin: a review. Drug Invest. 2(Suppl. 5), 2-8 (1990)